Allergen immunotherapy: progress and future outlook

References

• Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454:445–454.
   PubMed Web of Science ®Google Scholar
• Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol. 2021;21:739–751.
   PubMed Web of Science ®Google Scholar
• Pawankar RC, Holgate ST, Lockey RF, et al. The WAO white book on allergy. 2013.
   Google Scholar
• Pawankar R. Allergic diseases and asthma: a global public health concern and a call to action. World Allergy Organ J. 2014;7:12.
   PubMedGoogle Scholar
• Gupta RS, Springston EE, Warrier MR, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128:e9–17.
   PubMed Web of Science ®Google Scholar
• Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2 LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2022;77:734–766.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4:1.
   PubMed Web of Science ®Google Scholar
• Sturm GJ, Varga EM, Roberts G, et al. EAACI guidelines on allergen immunotherapy: hymenoptera venom allergy. Allergy. 2018;73:744–764.
   PubMed Web of Science ®Google Scholar
• Motosue MS, Bellolio MF, Van Houten HK, et al. Increasing emergency department visits for anaphylaxis, 2005-2014. J Allergy Clin Immunol Pract. 2017;5:171–175.
   PubMed Web of Science ®Google Scholar
• Turner PJ, Gowland MH, Sharma V, et al. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: an analysis of United Kingdom national anaphylaxis data, 1992-2012. J Allergy Clin Immunol. 2015;135:956–963.
   PubMed Web of Science ®Google Scholar
• Motosue MS, Bellolio MF, Van Houten HK, et al. Outcomes of emergency department anaphylaxis visits from 2005 to 2014. J Allergy Clin Immunol Pract. 2018;6:1002–1009.
   PubMed Web of Science ®Google Scholar
• Jeppesen AN, Christiansen CF, Frøslev T, et al. Hospitalization rates and prognosis of patients with anaphylactic shock in Denmark from 1995 through 2012. J Allergy Clin Immunol. 2016;137:1143–1147.
   PubMed Web of Science ®Google Scholar
• Liew WK, Williamson E, Tang ML. Anaphylaxis fatalities and admissions in Australia. J Allergy Clin Immunol. 2009;123:434–442.
   PubMed Web of Science ®Google Scholar
• Ma L, Danoff TM, Borish L. Case fatality and population mortality associated with anaphylaxis in the United States. J Allergy Clin Immunol. 2014;133:1075–1083.
   PubMed Web of Science ®Google Scholar
• Mullins RJ, Dear KB, Tang ML. Time trends in Australian hospital anaphylaxis admissions in 1998-1999 to 2011-2012. J Allergy Clin Immunol. 2015;136:367–375.
   PubMed Web of Science ®Google Scholar
• Tejedor-Alonso MA, Moro-Moro M, Mosquera González M, et al. Increased incidence of admissions for anaphylaxis in Spain 1998-2011. Allergy. 2015;70:880–883.
   PubMed Web of Science ®Google Scholar
• Turner PJ, Campbell DE, Motosue MS, et al. Global trends in anaphylaxis epidemiology and clinical implications. J Allergy Clin Immunol Pract. 2020;8:1169–1176.
   PubMed Web of Science ®Google Scholar
• Mullins RJ, Wainstein BK, Barnes EH, et al. Increases in anaphylaxis fatalities in Australia from 1997 to 2013. Clin Exp Allergy. 2016;46:1099–1110.
   PubMed Web of Science ®Google Scholar
• Parrish CP, Kim H. Food-induced anaphylaxis: an update. Curr Allergy Asthma Rep. 2018;18:41.
   PubMed Web of Science ®Google Scholar
• Anagnostou K. Anaphylaxis in children: epidemiology, risk factors and management. Curr Pediatr Rev. 2018;14:180–186.
   PubMed Web of Science ®Google Scholar
• Protudjer JLP, Olén O, Vetander M, et al. Milk- related symptoms and immunoglobulin E reactivity in Swedish children from early life to adolescence. Nutrients. 2018;10. DOI:10.3390/nu10050651
   PubMed Web of Science ®Google Scholar
• Jackson CM, Kaplan AN, Järvinen KM. Environmental exposures may hold the key; impact of air pollution, greenness, and rural/farm lifestyle on allergic outcomes. Curr Allergy Asthma Rep. 2023;23:77–91.
   PubMed Web of Science ®Google Scholar
• Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989;299:1259–1260.
   PubMed Web of Science ®Google Scholar
• Renz H, Skevaki C. Early life microbial exposures and allergy risks: opportunities for prevention. Nat Rev Immunol. 2021;21:177–191. DOI:10.1038/s41577-020-00420-y
   PubMed Web of Science ®Google Scholar
• Rook GA, Adams V, Hunt J, et al. Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders. Springer Semin Immunopathol. 2004;25:237–255.
   PubMed Web of Science ®Google Scholar
• Haahtela T. A biodiversity hypothesis. Allergy. 2019;74:1445–1456.
   PubMed Web of Science ®Google Scholar
• Baloh CH, Mathias RA. Recent progress in the genetic and epigenetic underpinnings of atopy. J Allergy Clin Immunol. 2023;151:60–69. DOI:10.1016/j.jaci.2022.10.027
   PubMed Web of Science ®Google Scholar
• Coombs PR, Gell PG. Classification of Allergic Reactions Responsible for Clinical Hypersensitivity and Disease. In: Gell RR editor. Clinical Aspects of Immunology. Oxford: Oxford University Press; 1968. p. 575–596.
   Google Scholar
• Abbas M, Moussa M, Akel H. Type I hypersensitivity reaction. StatPearls. Treasure Island (FL): StatPearls Publishing LLC; 2020.
   Google Scholar
• Alvaro-Lozano M, Akdis CA, Akdis M, et al. EAACI allergen immunotherapy user’s guide. Pediatr Allergy Immunol. 2020;31(25):1–101. DOI:10.1111/pai.13189
   PubMedGoogle Scholar
• Kucuksezer UC, Ozdemir C, Akdis M, et al. Precision/Personalized medicine in allergic diseases and asthma. Arch Immunol Ther Exp (Warsz). 2018;66:431–442.
   PubMed Web of Science ®Google Scholar
• Dong H, Hao Y, Li W, et al. IL-36 cytokines: their roles in asthma and potential as a therapeutic. Front Immunol. 2022;13:921275.
   PubMed Web of Science ®Google Scholar
• Halken S, Larenas-Linnemann D, Roberts G, et al. EAACI guidelines on allergen immunotherapy: prevention of allergy. Pediatr Allergy Immunol. 2017;28:728–745. DOI:10.1111/pai.12807
   PubMed Web of Science ®Google Scholar
• Kristiansen M, Dhami S, Netuveli G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2017;28:18–29.
   PubMed Web of Science ®Google Scholar
• Graversen JH, Madsen M, Moestrup SK. CD163: a signal receptor scavenging haptoglobin-hemoglobin complexes from plasma. Int J Biochem Cell Biol. 2002;34:309–314.
   PubMed Web of Science ®Google Scholar
• Pascual G, Glass CK. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab. 2006;17:321–327.
   PubMed Web of Science ®Google Scholar
• Kortekaas Krohn I, Callebaut I, Alpizar YA, et al. MP29-02 reduces nasal hyperreactivity and nasal mediators in patients with house dust mite-allergic rhinitis. Allergy. 2018;73:1084–1093.
   PubMed Web of Science ®Google Scholar
• Okano M. Mechanisms and clinical implications of glucocorticosteroids in the treatment of allergic rhinitis. Clin Exp Immunol. 2009;158:164–173.
   PubMed Web of Science ®Google Scholar
• (GINA) GIfA. Global strategy for asthma management and prevention 2021 [cited 2023 Jan 5]. Available from: https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf
   Google Scholar
• Eraso I, Sangiovanni S, Morales EI, et al. Aspirin desensitization in NSAID-exacerbated respiratory disease and its outcomes in the clinical course of asthma: a systematic review of the literature and meta-analysis. PLoS ONE. 2021;16:e0247871.
   PubMed Web of Science ®Google Scholar
• Dellon ES, Liacouras CA, Molina-Infante J, et al. Updated International consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference. Gastroenterology. 2018;155:1022–33.e10.
   PubMed Web of Science ®Google Scholar
• Aceves SS, Alexander JA, Baron TH, et al. Endoscopic approach to eosinophilic esophagitis: American Society for gastrointestinal endoscopy consensus conference. Gastrointest Endosc. 2022;96:576–92.e1.
   PubMed Web of Science ®Google Scholar
• Hirano I, Chan ES, Rank MA, et al. AGA institute and the joint task force on allergy-immunology practice parameters clinical guidelines for the management of eosinophilic esophagitis. Annals of Allergy, Asthma & Immunol. 2020;124:416–423.
   PubMed Web of Science ®Google Scholar
• Kettner L, Seitl I, Fischer L. Recent advances in the application of microbial diamine oxidases and other histamine-oxidizing enzymes. World J Microbiol Biotechnol. 2022;38:232.
   PubMed Web of Science ®Google Scholar
• Muraro A, Worm M, Alviani C, et al. EAACI guidelines: anaphylaxis (2021 update). Allergy. 2022;77:357–377.
   PubMed Web of Science ®Google Scholar
• Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75:1023–1042.
   PubMed Web of Science ®Google Scholar
• Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines-omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12-17 years old. Allergy. 2022;77:17–38.
   PubMed Web of Science ®Google Scholar
• CM J, Miller C, Senior B. Management of chronic rhinosinusitis with nasal polyposis in the Era of biologics. J Asthma Allergy. 2021;14:873–882.
   PubMed Web of Science ®Google Scholar
• Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014;2:525–36.e1.
   PubMed Web of Science ®Google Scholar
• Segal M, Stokes JR, Casale TB. Anti-immunoglobulin e therapy. World Allergy Organ J. 2008;1:174–183.
   PubMedGoogle Scholar
• Austin CD, Gonzalez Edick M, Ferrando RE, et al. A randomized, placebo-controlled trial evaluating effects of lebrikizumab on airway eosinophilic inflammation and remodelling in uncontrolled asthma (CLAVIER). Clin Exp Allergy. 2020;50:1342–1351.
   PubMed Web of Science ®Google Scholar
• Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines-recommendations for severe asthma. Allergy. 2021;76:14–44.
   PubMed Web of Science ®Google Scholar
• Maurer M, Khan DA, Elieh Ali Komi D, et al. Biologics for the use in chronic spontaneous Urticaria: when and which. J Allergy Clin Immunol Pract. 2021;9:1067–1078.
   PubMed Web of Science ®Google Scholar
• Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–2496.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–139.
   PubMed Web of Science ®Google Scholar
• Agache I, Akdis CA, Akdis M, et al. EAACI biologicals guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76:988–1009.
   PubMed Web of Science ®Google Scholar
• El-Qutob D. Off-label uses of omalizumab. Clin Rev Allergy Immunol. 2016;50:84–96.
   PubMed Web of Science ®Google Scholar
• Muñoz-Bellido FJ, Moreno E, Dávila I. Dupilumab: a review of present indications and off-label uses. J Investig Allergol Clin Immunol. 2022;32:97–115.
   PubMed Web of Science ®Google Scholar
• Gauvreau GM, O’Byrne PM, Boulet LP, et al. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014;370:2102–2110.
   PubMed Web of Science ®Google Scholar
• Corren J, Ambrose CS, Sałapa K, et al. Efficacy of tezepelumab in patients with severe, uncontrolled asthma and perennial allergy. J Allergy Clin Immunol Pract. 2021;9:4334–42.e6.
   PubMed Web of Science ®Google Scholar
• Dhami S, Kakourou A, Asamoah F, et al. Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy. 2017;72:1825–1848. DOI:10.1111/all.13208
   PubMed Web of Science ®Google Scholar
• Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy. 2017;72:1597–1631. DOI:10.1111/all.13201
   PubMed Web of Science ®Google Scholar
• Dhami S, Zaman H, Varga EM, et al. Allergen immunotherapy for insect venom allergy: a systematic review and meta-analysis. Allergy. 2017;72:342–365. DOI:10.1111/all.13077
   PubMed Web of Science ®Google Scholar
• Domdey A, Njue A, Nuabor W, et al. Allergy immunotherapies for allergic rhinitis: systematic review and assessment of evolving quality. Eur Ann Allergy Clin Immunol. 2019;51:147–158. DOI:10.23822/EurAnnACI.1764-1489.100
   PubMed Web of Science ®Google Scholar
• Roberts G, Pfaar O, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: allergic rhinoconjunctivitis. Allergy. 2018;73:765–798.
   PubMed Web of Science ®Google Scholar
• Walker SM, Durham SR, Till SJ, et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy. 2011;41:1177–1200.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Ankermann T, Augustin M, et al. Guideline on allergen immunotherapy in IgE-mediated allergic diseases: s2K guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), Medical Association of German Allergologists (AeDA), Austrian Society of Allergology and Immunology (ÖGAI), Swiss Society for Allergology and Immunology (SSAI), German Dermatological Society (DDG), German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), German Society of Pediatrics and Adolescent Medicine (DGKJ), Society of Pediatric Pulmonology (GPP), German Respiratory Society (DGP), German Professional Association of Otolaryngologists (BVHNO), German Association of Paediatric and Adolescent Care Specialists (BVKJ), Federal Association of Pneumologists, Sleep and Respiratory Physicians (BdP), Professional Association of German Dermatologists (BVDD). Allergol Select. 2022;6:167–232.
   PubMedGoogle Scholar
• Tie K, Miller C, Zanation AM, et al. Subcutaneous versus sublingual immunotherapy for adults with allergic rhinitis: a systematic review with meta-analyses. Laryngoscope. 2021;132:499–508.
   PubMed Web of Science ®Google Scholar
• Meadows A, Kaambwa B, Novielli N, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013;17:1–322.
   Web of Science ®Google Scholar
• Boldovjakova D, Cordoni S, Fraser CJ, et al. Sublingual immunotherapy vs placebo in the management of grass pollen-induced allergic rhinitis in adults: a systematic review and meta-analysis. Clin Otolaryngol. 2021;46:52–59.
   PubMed Web of Science ®Google Scholar
• Blanco C, Bazire R, Argiz L, et al. Sublingual allergen immunotherapy for respiratory allergy: a systematic review. Drugs Context. 2018;7:212552.
   PubMedGoogle Scholar
• Agache I, Lau S, Akdis CA, et al. EAACI guidelines on allergen immunotherapy: house dust mite-driven allergic asthma. Allergy. 2019;74:855–873.
   PubMed Web of Science ®Google Scholar
• Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127:S1–55.
   PubMed Web of Science ®Google Scholar
• Creticos PS, Bernstein DI, Casale TB, et al. Coseasonal initiation of allergen immunotherapy: a systematic review. J Allergy Clin Immunol Pract. 2016;4:1194–204.e4.
   PubMed Web of Science ®Google Scholar
• Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355:1445–1455.
   PubMed Web of Science ®Google Scholar
• Bonifazi F, Jutel M, Biló BM, et al. Prevention and treatment of hymenoptera venom allergy: guidelines for clinical practice. Allergy. 2005;60:1459–1470.
   PubMed Web of Science ®Google Scholar
• Patrawala M, Shih J, Lee G, et al. Peanut oral immunotherapy: a current perspective. Curr Allergy Asthma Rep. 2020;20:14. DOI:10.1007/s11882-020-00908-6
   PubMed Web of Science ®Google Scholar
• Vickery BP, Vereda A, Casale TB, et al. AR101 oral immunotherapy for peanut allergy. N Engl J Med. 2018;379:1991–2001.
   PubMed Web of Science ®Google Scholar
• Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for IgE-mediated food allergy: a systematic review and meta-analysis. Allergy. 2017;72:1133–1147. DOI:10.1111/all.13124
   PubMed Web of Science ®Google Scholar
• Gueguen C, Bouley J, Moussu H, et al. Changes in markers associated with dendritic cells driving the differentiation of either TH2 cells or regulatory T cells correlate with clinical benefit during allergen immunotherapy. J Allergy Clin Immunol. 2016;137:545–558.
   PubMed Web of Science ®Google Scholar
• Zimmer A, Bouley J, Le Mignon M, et al. A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy. J Allergy Clin Immunol. 2012;129:1020–1030.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Blesken T, Akdis M, et al. Role of interleukin 10 in specific immunotherapy. J Clin Invest. 1998;102:98–106.
   PubMed Web of Science ®Google Scholar
• Francis JN, James LK, Paraskevopoulos G, et al. Grass pollen immunotherapy: iL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol. 2008;121:1120–5.e2.
   PubMed Web of Science ®Google Scholar
• Bohle B, Kinaciyan T, Gerstmayr M, et al. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol. 2007;120:707–713.
   PubMed Web of Science ®Google Scholar
• O’Hehir RE, Gardner LM, de Leon MP, et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med. 2009;180:936–947.
   PubMed Web of Science ®Google Scholar
• Shamji MH, Layhadi JA, Achkova D, et al. Role of IL-35 in sublingual allergen immunotherapy. J Allergy Clin Immunol. 2019;143:1131–1142.
   PubMed Web of Science ®Google Scholar
• Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6:761–771. DOI:10.1038/nri1934
   PubMed Web of Science ®Google Scholar
• van der Heijden FL, van Neerven RJ J, van Katwijk M, et al. Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol. 1993;150:3643–3650.
   PubMed Web of Science ®Google Scholar
• Würtzen PA, Lund G, Lund K, et al. A double-blind placebo-controlled birch allergy vaccination study II: correlation between inhibition of IgE binding, histamine release and facilitated allergen presentation. Clin Exp Allergy. 2008;38:1290–1301.
   PubMed Web of Science ®Google Scholar
• Hamid QA, Schotman E, Jacobson MR, et al. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J Allergy Clin Immunol. 1997;99:254–260.
   PubMed Web of Science ®Google Scholar
• van de Veen W, Stanic B, Yaman G, et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol. 2013;131:1204–1212.
   PubMed Web of Science ®Google Scholar
• Boonpiyathad T, van de Veen W, Wirz O, et al. Role of Der p 1-specific B cells in immune tolerance during 2 years of house dust mite-specific immunotherapy. J Allergy Clin Immunol. 2019;143:1077–86.e10.
   PubMed Web of Science ®Google Scholar
• Lao-Araya M, Steveling E, Scadding GW, et al. Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy. J Allergy Clin Immunol. 2014;134:1193–1195.
   PubMed Web of Science ®Google Scholar
• Golebski K, Layhadi JA, Sahiner U, et al. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. Immunity. 2021;54:291–307.e7.
   PubMed Web of Science ®Google Scholar
• Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, et al. Allergen immunotherapy for atopic dermatitis: systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol. 2023;151:147–158.
   PubMed Web of Science ®Google Scholar
• Boyle RJ, Elremeli M, Hockenhull J, et al. Venom immunotherapy for preventing allergic reactions to insect stings. Cochrane Database Syst Rev. 2012;10:Cd008838.
   PubMedGoogle Scholar
• Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014;134:568–575.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315:1715–1725.
   PubMed Web of Science ®Google Scholar
• Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999;341:468–475.
   PubMed Web of Science ®Google Scholar
• Bozek A, Cudak A, Walter Canonica G. Long-term efficacy of injected allergen immunotherapy for treatment of grass pollen allergy in elderly patients with allergic rhinitis. Allergy Asthma Proc. 2020;41:271–277.
   PubMed Web of Science ®Google Scholar
• Penagos M, Durham SR. Allergen immunotherapy for long-term tolerance and prevention. J Allergy Clin Immunol. 2022;149:802–811. DOI:10.1016/j.jaci.2022.01.007
   PubMed Web of Science ®Google Scholar
• Chu DK, Wood RA, French S, et al. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019;393:2222–2232. DOI:10.1016/S0140-6736(19)30420-9
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration, HHS. International conference on harmonisation; guidance on E15 pharmacogenomics definitions and sample coding; availability. Notice Fed Regist. 2008;73:19074–19076.
   PubMedGoogle Scholar
• López JF, Bel Imam M, Satitsuksanoa P, et al. Mechanisms and biomarkers of successful allergen-specific immunotherapy. Asia Pac Allergy. 2022;12:e45.
   PubMed Web of Science ®Google Scholar
• Shamji MH, Kappen JH, Akdis M, et al. Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI position paper. Allergy. 2017;72:1156–1173. DOI:10.1111/all.13138
   PubMed Web of Science ®Google Scholar
• Breiteneder H, Peng YQ, Agache I, et al. Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma. Allergy. 2020;75:3039–3068.
   PubMed Web of Science ®Google Scholar
• Jakwerth CA, Kitzberger H, Pogorelov D, et al. Role of microRnas in type 2 diseases and allergen-specific immunotherapy. Front Allergy. 2022;3:993937.
   PubMedGoogle Scholar
• Di Lorenzo G, Mansueto P, Pacor ML, et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;123:1103–1110.
   PubMed Web of Science ®Google Scholar
• Nogami K, Nagao M, Takase T, et al. House dust mite subcutaneous immunotherapy and lung function trajectory in children and adolescents with asthma. Children (Basel). 2022;9:487.
   PubMed Web of Science ®Google Scholar
• Floch V BL, Berjont N, Batard T, et al. Coordinated IgG2 and IgE responses as a marker of allergen immunotherapy efficacy. Allergy. 2022;77:1263–1273.
   PubMed Web of Science ®Google Scholar
• Heeringa JJ, McKenzie CI, Varese N, et al. Induction of IgG(2) and IgG(4) B-cell memory following sublingual immunotherapy for ryegrass pollen allergy. Allergy. 2020;75:1121–1132.
   PubMed Web of Science ®Google Scholar
• Mothes N, Heinzkill M, Drachenberg KJ, et al. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy. 2003;33:1198–1208.
   PubMed Web of Science ®Google Scholar
• Bianchini R, Karagiannis SN, Jordakieva G, et al. The Role of IgG4 in the fine tuning of tolerance in IgE-mediated allergy and cancer. Int J Mol Sci. 2020:21. DOI:10.3390/ijms21145017
   PubMed Web of Science ®Google Scholar
• Nikolov G, Todordova Y, Emilova R, et al. Allergen-specific IgE and IgG4 as biomarkers for immunologic changes during subcutaneous allergen immunotherapy. Antibodies (Basel). 2021;10:49.
   PubMedGoogle Scholar
• James LK, Till SJ. Potential mechanisms for IgG4 inhibition of immediate hypersensitivity reactions. Curr Allergy Asthma Rep. 2016;16:23.
   PubMed Web of Science ®Google Scholar
• Gehlhar K, Schlaak M, Becker W, et al. Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy. 1999;29:497–506. DOI:10.1046/j.1365-2222.1999.00525.x
   PubMed Web of Science ®Google Scholar
• Gómez E, Fernández TD, Doña I, et al. Initial immunological changes as predictors for house dust mite immunotherapy response. Clin Exp Allergy. 2015;45:1542–1553.
   PubMed Web of Science ®Google Scholar
• Yang L, Yang Y, Xu Q, et al. Specific IgE and IgG4 profiles of house dust mite components in allergen-specific immunotherapy. Front Immunol. 2021;12:786738.
   PubMed Web of Science ®Google Scholar
• Li Q, Li M, Yue W, et al. Predictive factors for clinical response to allergy immunotherapy in children with asthma and rhinitis. Int Arch Allergy Immunol. 2014;164:210–217.
   PubMed Web of Science ®Google Scholar
• Van Overtvelt L, Baron-Bodo V, Horiot S, et al. Changes in basophil activation during grass-pollen sublingual immunotherapy do not correlate with clinical efficacy. Allergy. 2011;66:1530–1537.
   PubMed Web of Science ®Google Scholar
• Eifan AO, Akkoc T, Yildiz A, et al. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy. 2010;40:922–932.
   PubMed Web of Science ®Google Scholar
• Shamji MH, Kappen J, Abubakar-Waziri H, et al. Nasal allergen-neutralizing IgG(4) antibodies block IgE-mediated responses: novel biomarker of subcutaneous grass pollen immunotherapy. J Allergy Clin Immunol. 2019;143:1067–1076.
   PubMed Web of Science ®Google Scholar
• Shamji MH, Francis JN, Würtzen PA, et al. Cell-free detection of allergen-IgE cross-linking with immobilized phase CD23: inhibition by blocking antibody responses after immunotherapy. J Allergy Clin Immunol. 2013;132:1003–1005.
   PubMed Web of Science ®Google Scholar
• Shamji MH, Wilcock LK, Wachholz PA, et al. The IgE-facilitated allergen binding (FAB) assay: validation of a novel flow-cytometric based method for the detection of inhibitory antibody responses. J Immunol Methods. 2006;317:71–79.
   PubMed Web of Science ®Google Scholar
• Schroeder JT, Kagey-Sobotka A, Lichtenstein LM. The role of the basophil in allergic inflammation. Allergy. 1995;50:463–472.
   PubMed Web of Science ®Google Scholar
• MacGlashan D Jr. Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes. Clin Exp Allergy. 2010;40:1365–1377.
   PubMed Web of Science ®Google Scholar
• Hoffmann HJ, Santos AF, Mayorga C, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy. 2015;70:1393–1405. DOI:10.1111/all.12698
   PubMed Web of Science ®Google Scholar
• Chinthrajah RS, Purington N, Andorf S, et al. Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2019;394:1437–1449.
   PubMed Web of Science ®Google Scholar
• Caruso M, Cibella F, Emma R, et al. Basophil biomarkers as useful predictors for sublingual immunotherapy in allergic rhinitis. Int Immunopharmacol. 2018;60:50–58.
   PubMed Web of Science ®Google Scholar
• Patil SU, Steinbrecher J, Calatroni A, et al. Early decrease in basophil sensitivity to Ara h 2 precedes sustained unresponsiveness after peanut oral immunotherapy. J Allergy Clin Immunol. 2019;144:1310–1319.
   PubMed Web of Science ®Google Scholar
• Ihara F, Sakurai D, Yonekura S, et al. Identification of specifically reduced Th2 cell subsets in allergic rhinitis patients after sublingual immunotherapy. Allergy. 2018;73:1823–1832.
   PubMed Web of Science ®Google Scholar
• Xie S, Fan R, Tang Q, et al. Identification of robust biomarkers for early predicting efficacy of subcutaneous immunotherapy in children with house dust mite-induced allergic rhinitis by multiple cytokine profiling. Front Immunol. 2021;12:805404.
   PubMed Web of Science ®Google Scholar
• Cheng S, Wen S, Xie S, et al. Circulating C-X-C motif ligand 13 as a biomarker for early predicting efficacy of subcutaneous immunotherapy in children with chronic allergic rhinitis. Front Pediatr. 2022;10:872152.
   PubMed Web of Science ®Google Scholar
• Ma TT, Cao MD, Yu RL, et al. Leukotriene A(4) hydrolase is a candidate predictive biomarker for successful allergen immunotherapy. Front Immunol. 2020;11:559746.
   PubMed Web of Science ®Google Scholar
• Guéguen C, Luce S, Lombardi V, et al. IL-10 mRNA levels in whole blood cells correlate with house dust mite allergen immunotherapy efficacy. Allergy. 2019;74:2223–2226.
   PubMed Web of Science ®Google Scholar
• Sakurai D, Yonekura S, Iinuma T, et al. Sublingual immunotherapy for allergic rhinitis: subjective versus objective tools to evaluate its success. Rhinology. 2016;54:221–230.
   PubMed Web of Science ®Google Scholar
• Xie S, Jiang S, Zhang H, et al. Prediction of sublingual immunotherapy efficacy in allergic rhinitis by serum metabolomics analysis. Int Immunopharmacol. 2021;90:107211.
   PubMed Web of Science ®Google Scholar
• Rolland JM, Gardner LM, O’Hehir RE. Functional regulatory T cells and allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2010;10:559–566.
   PubMed Web of Science ®Google Scholar
• Radulovic S, Jacobson MR, Durham SR, et al. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol. 2008;121:1467–1472.
   PubMed Web of Science ®Google Scholar
• Scadding GW, Shamji MH, Jacobson MR, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin a and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy. 2010;40:598–606.
   PubMed Web of Science ®Google Scholar
• Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol. 2012;30:221–241.
   PubMed Web of Science ®Google Scholar
• Stanic B, van de Veen W, Wirz OF, et al. IL-10-overexpressing B cells regulate innate and adaptive immune responses. J Allergy Clin Immunol. 2015;135:771–780.
   PubMed Web of Science ®Google Scholar
• Angelini F, Pacciani V, Corrente S, et al. Dendritic cells modification during sublingual immunotherapy in children with allergic symptoms to house dust mites. World J Pediatr. 2011;7:24–30.
   PubMed Web of Science ®Google Scholar
• Piconi S, Trabattoni D, Rainone V, et al. Immunological effects of sublingual immunotherapy: clinical efficacy is associated with modulation of programmed cell death ligand 1, IL-10, and IgG4. J Immunol. 2010;185:7723–7730.
   PubMed Web of Science ®Google Scholar
• Syed A, Garcia MA, Lyu SC, et al. Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). J Allergy Clin Immunol. 2014;133:500–510.
   PubMed Web of Science ®Google Scholar
• Guideline on the Clinical Development of Products for Specific Immunotherapy for the Treatment of Allergic Diseases [ Cited 2023 Mar 04]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-development-products-specific-immunotherapy-treatment-allergic-diseases_en.pdf.
   Google Scholar
• Petsky HL, Kew KM, Chang AB. Exhaled nitric oxide levels to guide treatment for children with asthma. Cochrane Database Syst Rev. 2016;11:Cd011439.
   PubMedGoogle Scholar
• Petsky HL, Kew KM, Turner C, et al. Exhaled nitric oxide levels to guide treatment for adults with asthma. Cochrane Database Syst Rev. 2016;9:Cd011440.
   PubMedGoogle Scholar
• Gauvreau GM, Davis BE, Scadding G, et al. Allergen provocation tests in respiratory research: building on 50 years of experience. Eur Respir J. 2022;60(2):2102782. DOI:10.1183/13993003.02782-2021
   PubMed Web of Science ®Google Scholar
• Horak F, Zieglmayer P, Zieglmayer R, et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J Allergy Clin Immunol. 2009;124:471–477.
   PubMed Web of Science ®Google Scholar
• Scadding GW, Eifan A, Penagos M, et al. Local and systemic effects of cat allergen nasal provocation. Clin Exp Allergy. 2015;45:613–623.
   PubMedGoogle Scholar
• Pfaar O, Calderon MA, Andrews CP, et al. Allergen exposure chambers: harmonizing current concepts and projecting the needs for the future - an EAACI position paper. Allergy. 2017;72:1035–1042.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Zieglmayer P. Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy. Clin Transl Allergy. 2020;10:33.
   PubMed Web of Science ®Google Scholar
• Hossenbaccus L, Steacy LM, Walker T, et al. Utility of environmental exposure unit challenge protocols for the study of allergic rhinitis therapies. Curr Allergy Asthma Rep. 2020;20:34.
   PubMed Web of Science ®Google Scholar
• Jacobs RL, Harper N, He W, et al. Effect of confounding cofactors on responses to pollens during natural season versus pollen challenge chamber exposure. J Allergy Clin Immunol. 2014;133:1340–1346.
   PubMed Web of Science ®Google Scholar
• Ellis AK, Jacobs RL, Tenn MW, et al. Clinical standardization of two controlled allergen challenge facilities: the environmental exposure unit and the biogenics research chamber. Annals of Allergy, Asthma & Immunol. 2019;122:639–46.e2.
   PubMed Web of Science ®Google Scholar
• Larson D, Patel P, Salapatek AM, et al. Nasal allergen challenge and environmental exposure chamber challenge: a randomized trial comparing clinical and biological responses to cat allergen. J Allergy Clin Immunol. 2020;145:1585–1597.
   PubMed Web of Science ®Google Scholar
• Scadding GW, Calderon MA, Bellido V, et al. Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes. J Immunol Methods. 2012;384:25–32.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI position paper. Allergy. 2014;69:854–867.
   PubMed Web of Science ®Google Scholar
• Sousa-Pinto B, Azevedo LF, Jutel M, et al. Development and validation of combined symptom-medication scores for allergic rhinitis. Allergy. 2022;77:2147–2162.
   PubMed Web of Science ®Google Scholar
• DuBuske LM, Frew AJ, Horak F, et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc. 2011;32:239–247.
   PubMed Web of Science ®Google Scholar
• Kirtland ME, Tsitoura DC, Durham SR, et al. Toll-like receptor agonists as adjuvants for allergen immunotherapy. Front Immunol. 2020;11:599083. DOI:10.3389/fimmu.2020.599083
   PubMed Web of Science ®Google Scholar
• Jutel M, Jaeger L, Suck R, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116:608–613. DOI:10.1016/j.jaci.2005.06.004
   PubMed Web of Science ®Google Scholar
• Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008;122:951–960. DOI:10.1016/j.jaci.2008.09.017
   PubMed Web of Science ®Google Scholar
• Corrigan CJ, Kettner J, Doemer C, et al. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy. 2005;60:801–807. DOI:10.1111/j.1398-9995.2005.00790.x
   PubMed Web of Science ®Google Scholar
• Mösges R, Rohdenburg C, Eichel A, et al. Dose-finding study of carbamylated monomeric allergoid tablets in grass-allergic rhinoconjunctivitis patients. Immunotherapy. 2017;9:1225–1238.
   PubMed Web of Science ®Google Scholar
• Atanasio A, Franklin MC, Kamat V, et al. Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response. J Allergy Clin Immunol. 2022;149:200–211. DOI:10.1016/j.jaci.2021.05.038
   PubMed Web of Science ®Google Scholar
• Orengo JM, Radin AR, Kamat V, et al. Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement. Nat Commun. 2018;9:1421. DOI:10.1038/s41467-018-03636-8
   PubMed Web of Science ®Google Scholar
• Har D, Lee MJ. Systemic reaction rates with omalizumab, subcutaneous immunotherapy, and combination therapy in children with allergic asthma. Allergy Asthma Proc. 2019;40:35–40.
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Martignago I, Ridolo E. Use of a combination of allergen immunotherapy and omalizumab for prevention of anaphylaxis. Current Treatment Options in Allergy. 2018;5:155–165. DOI:10.1007/s40521-018-0170-8
   Google Scholar
• Atipas K, Kanjanawasee D, Tantilipikorn P. Intradermal allergen immunotherapy for allergic rhinitis: current evidence. J Pers Med. 2022;12:12.
   Web of Science ®Google Scholar
• Slovick A, Douiri A, Muir R, et al. Intradermal grass pollen immunotherapy increases T(H)2 and IgE responses and worsens respiratory allergic symptoms. J Allergy Clin Immunol. 2017;139:1830–9.e13.
   PubMed Web of Science ®Google Scholar
• Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012;129:128–135.
   PubMed Web of Science ®Google Scholar
• Senti G, von Moos S, Tay F, et al. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials. Allergy. 2015;70:707–710.
   PubMed Web of Science ®Google Scholar
• Zylke JW. Epicutaneous immunotherapy vs placebo for peanut protein ingestion among peanut-allergic children. JAMA. 2019;321:956.
   PubMed Web of Science ®Google Scholar
• von Moos S, Johansen P, Tay F, et al. Comparing safety of abrasion and tape-stripping as skin preparation in allergen-specific epicutaneous immunotherapy. J Allergy Clin Immunol. 2014;134:965–967.
   PubMed Web of Science ®Google Scholar
• Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;124:997–1002.
   PubMed Web of Science ®Google Scholar
• Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008;105:17908–17912. DOI:10.1073/pnas.0803725105
   PubMed Web of Science ®Google Scholar
• Slifka MK, Amanna IJ. Chapter: 8 Passive Immunization. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM editors. Plotkin’s Vaccines. 7th ed. 2018. p. 84–95.e10. DOI;10.1016/B978-0-323-35761-6.00008-0
   Google Scholar
• Albrecht M, Arck PC. Vertically transferred immunity in neonates: mothers, mechanisms and mediators. Front Immunol. 2020;11:555.
   PubMed Web of Science ®Google Scholar
• Behring K. On the development of immunity to diphtheria and tetanus in animals. Dtsch Med Wochenschr. 1965;90:2183.
   PubMedGoogle Scholar
• Grundbacher FJ. Behring’s discovery of diphtheria and tetanus antitoxins. Immunol Today. 1992;13:188–190.
   PubMedGoogle Scholar
• Marcotte H, Hammarström L. Chapter: 71 Passive Immunization: Toward Magic Bullets. In: Mestecky J, Strober W, Russell MW, Kelsall BL, Cheroutre H, Lambrecht BN. editors. Mucosal Immunology. 4th ed. Academic Press; 2015. p. 1403–1434. DOI:10.1016/B978-0-12-415847-4.00071-9
   Google Scholar
• Manohar A, Ahuja J, Crane JK. Immunotherapy for infectious diseases: past, present, and future. Immunol Invest. 2015;44:731–737.
   PubMed Web of Science ®Google Scholar
• Prausnitz CH. Küstner: Studien über die Überempfindlichkeit. Centralbl F Bakt(orig). 1921;86:16.
   Google Scholar
• Johansson SG, Bennich H. Immunological studies of an atypical (myeloma) immunoglobulin. Immunology. 1967;13:381–394.
   PubMed Web of Science ®Google Scholar
• Ishizaka K, Ishizaka T, Hornbrook MM. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol. 1966;97:75–85.
   PubMed Web of Science ®Google Scholar
• Cooke RA, Barnard JH, Hebald S, et al. Serological evidence of immunity with coexisting sensitization in a type of human allergy (hay fever). J Exp Med. 1935;62:733–750.
   PubMedGoogle Scholar
• Lighaam LC, Rispens T. The immunobiology of immunoglobulin G4. Semin Liver Dis. 2016;36:200–215.
   PubMed Web of Science ®Google Scholar
• Flicker S, Steinberger P, Norderhaug L, et al. Conversion of grass pollen allergen-specific human IgE into a protective IgG(1) antibody. Eur J Immunol. 2002;32:2156–2162.
   PubMed Web of Science ®Google Scholar
• Zinkhan S, Thoms F, Augusto G, et al. On the role of allergen-specific IgG subclasses for blocking human basophil activation. Front Immunol. 2022;13:892631.
   PubMed Web of Science ®Google Scholar
• Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol. 2003;132:13–24. DOI:10.1159/000073260
   PubMed Web of Science ®Google Scholar
• James LK. The cloning and expression of human monoclonal antibodies: implications for allergen immunotherapy. Curr Allergy Asthma Rep. 2016;16:15. DOI:10.1007/s11882-015-0588-z
   PubMed Web of Science ®Google Scholar
• Matson AP, Thrall RS, Rafti E, et al. Breastmilk from allergic mothers can protect offspring from allergic airway inflammation. Breastfeed Med. 2009;4:167–174.
   PubMed Web of Science ®Google Scholar
• Lupinek C, Hochwallner H, Johansson C, et al. Maternal allergen-specific IgG might protect the child against allergic sensitization. J Allergy Clin Immunol. 2019;144:536–548.
   PubMed Web of Science ®Google Scholar
• Flicker S, Linhart B, Wild C, et al. Passive immunization with allergen-specific IgG antibodies for treatment and prevention of allergy. Immunobiology. 2013;218:884–891.
   PubMed Web of Science ®Google Scholar
• Storni F, Cabral-Miranda G, Roesti E, et al. A single monoclonal antibody against the peanut allergen Ara h 2 protects against systemic and local peanut allergy. Int Arch Allergy Immunol. 2020;181:334–341.
   PubMed Web of Science ®Google Scholar
• Paolucci M, Wuillemin N, Homère V, et al. Targeting Ara h 2 with human-derived monoclonal antibodies prevents peanut-induced anaphylaxis in mice. Allergy. 2023. DOI:10.1111/all.15659
   PubMed Web of Science ®Google Scholar
• Shamji MH, Singh I, Layhadi JA, et al. Passive prophylactic administration with a single dose of anti-fel d 1 monoclonal antibodies REGN1908-1909 in cat allergen-induced allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. Am J Respir Crit Care Med. 2021;204:23–33. DOI:10.1164/rccm.202011-4107OC
   PubMed Web of Science ®Google Scholar
• Gevaert P, De Craemer J, De Ruyck N, et al. Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study. J Allergy Clin Immunol. 2022;149:189–199. DOI:10.1016/j.jaci.2021.05.039
   PubMed Web of Science ®Google Scholar
• Flicker S, Gadermaier E, Madritsch C, et al. Passive immunization with allergen-specific antibodies. Curr Top Microbiol Immunol. 2011;352:141–159.
   PubMed Web of Science ®Google Scholar
• Wickman M. When allergies complicate allergies. Allergy. 2005;60(79):14–18.
   PubMedGoogle Scholar
• Satyaraj E, Wedner HJ, Bousquet J. Keep the cat, change the care pathway: a transformational approach to managing Fel d 1, the major cat allergen. Allergy. 2019;74(107):5–17.
   PubMedGoogle Scholar
• Strait RT. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc RIIb cross-linking. J Clin Invest. 2006;116:833–841.
   PubMed Web of Science ®Google Scholar
• Eckl-Dorna J, Villazala-Merino S, Linhart B, et al. Allergen-specific antibodies regulate secondary allergen-specific immune responses. Front Immunol. 2018;9:3131.
   PubMed Web of Science ®Google Scholar
• Wachholz PA, Soni NK, Till SJ, et al. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol. 2003;112:915–922.
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Huitema AD, Schellens JH, et al. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49:493–507.
   PubMed Web of Science ®Google Scholar
• Kamal MA, Dingman R, Wang CQ, et al. REGN1908-1909 monoclonal antibodies block Fel d 1 in cat allergic subjects: translational pharmacokinetics and pharmacodynamics. Clin Transl Sci. 2021;14:2440–2449.
   PubMed Web of Science ®Google Scholar
• Baldo BA. Immune- and non-immune-mediated adverse effects of monoclonal antibody therapy: a survey of 110 approved antibodies. Antibodies (Basel). 2022;11:17.
   PubMedGoogle Scholar
• Bernstein IL, Michael JG, Malkiel S, et al. Immunoregulatory function of specific IgG. II. Clinical evaluation of combined active and passive immunotherapy. Int Arch Allergy Appl Immunol. 1979;58:30–37.
   PubMedGoogle Scholar
• Bousquet J, Fontez A, Aznar R, et al. Combination of passive and active immunization in honeybee venom immunotherapy. J Allergy Clin Immunol. 1987;79:947–954.
   PubMed Web of Science ®Google Scholar
• Müller UR, Morris T, Bischof M, et al. Combined active and passive immunotherapy in honeybee-sting allergy. J Allergy Clin Immunol. 1986;78:115–122.
   PubMed Web of Science ®Google Scholar
• Casale TB, Busse WW, Kline JN, et al. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117:134–140.
   PubMed Web of Science ®Google Scholar
• Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125:383–389.
   PubMed Web of Science ®Google Scholar
• Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol. 2002;109:274–280.
   PubMed Web of Science ®Google Scholar
• Kopp MV, Hamelmann E, Zielen S, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma. Clin Exp Allergy. 2009;39:271–279.
   PubMed Web of Science ®Google Scholar
• Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal application of anti-IgE after preseasonal specific immunotherapy decreases ocular and nasal symptom scores and rescue medication use in grass pollen allergic children. Allergy. 2004;59:973–979.
   PubMed Web of Science ®Google Scholar
• Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy. 2018;73:799–815.
   PubMed Web of Science ®Google Scholar
• Passanisi S, Caminiti L, Zirilli G, et al. Biologics in food allergy: up-to-date. Expert Opin Biol Ther. 2021;21:1227–1235. DOI:10.1080/14712598.2021.1904888
   PubMed Web of Science ®Google Scholar
• Reinwald S, Rolland JM, O’Hehir RE, et al. Peanut oral immunotherapy: current trends in clinical trials. Immunother Adv. 2022;2:4. DOI:10.1093/immadv/ltac004
   Google Scholar
• Langlois A, Lavergne MH, Leroux H, et al. Protocol for a double-blind, randomized controlled trial on the dose-related efficacy of omalizumab in multi-food oral immunotherapy. Allergy, Asthma Clin Immunol. 2020;16:25.
   PubMed Web of Science ®Google Scholar
• Brandström J, Vetander M, Sundqvist AC, et al. Individually dosed omalizumab facilitates peanut oral immunotherapy in peanut allergic adolescents. Clin Exp Allergy. 2019;49:1328–1341.
   PubMed Web of Science ®Google Scholar
• Omalizumab as monotherapy and as adjunct therapy to multi-allergen OIT in food allergic participants (OUtMATCH). Identifier: nCT03881696. [cited 2023 Mar 4]. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT03881696:
   Google Scholar
• Wood RA, Kim JS, Lindblad R, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137:1103–1110.
   PubMed Web of Science ®Google Scholar
• Dupilumab as an adjunct for subcutaneous grass immunotherapy. Identifier NCT03558997. [cited 2023 Mar 4]. [Internet]. Available from: https://ClinicalTrials.gov/show/NCT03558997
   Google Scholar
• Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction. Identifier NCT04502966. [Internet]. [ cited 2023 Mar 04]. Available from: https://ClinicalTrials.gov/show/NCT04502966
   Google Scholar
• Study in pediatric subjects with peanut allergy to evaluate efficacy and safety of dupilumab as adjunct to AR101 (Peanut oral immunotherapy). Identifier NCT03682770. [ cited 2023 Mar 04]. [Internet]. Available from: https://ClinicalTrials.gov/show/NCT03682770
   Google Scholar
• Clinical study using biologics to improve multi OIT outcomes. Identifier NCT03679676. [ cited 2023 Mar 04] [Internet]. Available from: https://ClinicalTrials.gov/show/NCT03679676
   Google Scholar
• Dupilumab and milk OIT for the treatment of cow’s milk allergy. Identifier NCT04148352. [cited 2023 Mar 04] [Internet]. Available from: https://ClinicalTrials.gov/show/NCT04148352
   Google Scholar
• Burbank AJ, Sood P, Vickery BP, et al. Oral immunotherapy for food allergy. Immunol Allergy Clin North Am. 2016;36:55–69.
   PubMed Web of Science ®Google Scholar
• Sampath V, Sindher SB, Alvarez Pinzon AM, et al. Can food allergy be cured? What are the future prospects? Allergy. 2020;75:1316–1326.
   PubMed Web of Science ®Google Scholar
• MHK H, Wong WHS, Heine RG, et al. Early clinical predictors of remission of peanut allergy in children. J Allergy Clin Immunol. 2008;121:731–736.
   PubMed Web of Science ®Google Scholar
• Pouessel G, Lezmi G. Oral immunotherapy for food allergy: translation from studies to clinical practice? World Allergy Organ J. 2023;16:100747.
   PubMed Web of Science ®Google Scholar
• Grabenhenrich LB, Dölle S, Moneret-Vautrin A, et al. Anaphylaxis in children and adolescents: the European anaphylaxis registry. J Allergy Clin Immunol. 2016;137:1128–37.e1.
   PubMed Web of Science ®Google Scholar
• Herbert L, Marchisotto MJ, Vickery B. Patients’ perspectives and needs on novel food allergy treatments in the United States. Curr Treat Options Allergy. 2021;8:9–20.
   PubMedGoogle Scholar
• Fernandez-Rivas M, Vereda A, Vickery BP, et al. Open-label follow-on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy. Allergy. 2022;77:991–1003.
   PubMed Web of Science ®Google Scholar
• Bajzik V, DeBerg HA, Garabatos N, et al. Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses. Allergy. 2022;77:2534–2548.
   PubMed Web of Science ®Google Scholar
• Wambre E, Bajzik V, DeLong JH, et al. A phenotypically and functionally distinct human T(H)2 cell subpopulation is associated with allergic disorders. Sci Transl Med. 2017;9. DOI:10.1126/scitranslmed.aam9171
   PubMed Web of Science ®Google Scholar
• Vickery BP, Scurlock AM, Kulis M, et al. Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy. J Allergy Clin Immunol. 2014;133:468–475.
   PubMed Web of Science ®Google Scholar
• Lazizi S, Labrosse R, Graham F. Transitioning peanut oral immunotherapy to clinical practice. Front Allergy. 2022;3:974250.
   PubMedGoogle Scholar
• Yu W, Freeland DMH, Nadeau KC. Food allergy: immune mechanisms, diagnosis and immunotherapy. Nat Rev Immunol. 2016;16:751–765. DOI:10.1038/nri.2016.111
   PubMed Web of Science ®Google Scholar
• Jones SM, Kim EH, Nadeau KC, et al. Efficacy and safety of oral immunotherapy in children aged 1-3 years with peanut allergy (the immune tolerance network IMPACT trial): a randomised placebo-controlled study. Lancet. 2022;399:359–371.
   PubMed Web of Science ®Google Scholar
• Elizur A, Appel MY, Nachshon L, et al. Walnut oral immunotherapy for desensitisation of walnut and additional tree nut allergies (Nut CRACKER): a single-centre, prospective cohort study. Lancet Child & Adolescent Health. 2019;3:312–321.
   Web of Science ®Google Scholar
• Elizur A, Appel MY, Nachshon L, et al. Cashew oral immunotherapy for desensitizing cashew-pistachio allergy (NUT CRACKER study). Allergy. 2022;77:1863–1872.
   PubMed Web of Science ®Google Scholar
• Nowak-Węgrzyn A, Wood RA, Nadeau KC, et al. Multicenter, randomized, double-blind, placebo-controlled clinical trial of vital wheat gluten oral immunotherapy. J Allergy Clin Immunol. 2019;143:651–661.
   PubMed Web of Science ®Google Scholar
• Palosuo K, Karisola P, Savinko T, et al. A randomized, open-label trial of hen’s egg oral immunotherapy: efficacy and humoral immune responses in 50 children. J Allergy Clin Immunol Pract. 2021;9:1892–1901.
   PubMed Web of Science ®Google Scholar
• Maeda M, Imai T, Ishikawa R, et al. Effect of oral immunotherapy in children with milk allergy: the ORIMA study. Allergol Int. 2021;70:223–228.
   PubMed Web of Science ®Google Scholar
• Epstein-Rigbi N, Levy MB, Nachshon L, et al. Efficacy and safety of food allergy oral immunotherapy in adults. Allergy. 2022;78:803–811.
   PubMed Web of Science ®Google Scholar
• Wang J. Management of the patient with multiple food allergies. Curr Allergy Asthma Rep. 2010;10:271–277.
   PubMed Web of Science ®Google Scholar
• Gasich L, Fergeson J, Ly J. Multi-food oral immunotherapy as safe and effective as single food therapy. J Allergy Clin Immunol. 2020;145:AB133.
   Web of Science ®Google Scholar
• Bégin P, Winterroth LC, Dominguez T, et al. Safety and feasibility of oral immunotherapy to multiple allergens for food allergy. Allergy, Asthma & Clin Immunol. 2014;10:1.
   PubMed Web of Science ®Google Scholar
• Taudorf E, Weeke B. Orally administered grass pollen. Allergy. 1983;38:561–564.
   PubMed Web of Science ®Google Scholar
• Durham SR, Shamji MH. Allergen immunotherapy: past, present and future. Nat Rev Immunol. 2022;1–12. DOI:10.1038/s41577-022-00786-1
   PubMed Web of Science ®Google Scholar
• Perkin MR. Palforzia for peanut allergy: panacea or predicament. Clin Exp Allergy. 2022;52:729–731.
   PubMed Web of Science ®Google Scholar
• Mustafa SS, Patrawala S. Real world adoption of FDA-approved peanut oral immunotherapy with palforzia. J Allergy Clin Immunol. 2021;147:108.
   Web of Science ®Google Scholar
• Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 2009;9:537–543.
   PubMed Web of Science ®Google Scholar
• Hoang MP, Seresirikachorn K, Chitsuthipakorn W, et al. Intralymphatic immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Rhinology. 2021;59:236–244.
   PubMed Web of Science ®Google Scholar
• Werner MT, Bosso JV. Intralymphatic immunotherapy for allergic rhinitis: a systematic review and meta-analysis. Allergy Asthma Proc. 2021;42:283–292.
   PubMed Web of Science ®Google Scholar
• Hoffmann HJ, Hviid-Vyff B. Strengthening the case for intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 2022;22:387–395.
   PubMed Web of Science ®Google Scholar
• Konradsen JR, Grundstrom J, Hellkvist L, et al. Intralymphatic immunotherapy in pollen-allergic young adults with rhinoconjunctivitis and mild asthma: a randomized trial. J Allergy Clin Immunol. 2020;145:1005–7 e7.
   PubMed Web of Science ®Google Scholar
• Hellkvist L, Hjalmarsson E, Weinfeld D, et al. High dose pollen intralymphatic immunotherapy: two RDBPC trials question the benefit of dose increase. Allergy. 2021;77(3): 883–896. DOI:10.1111/all.15042
   PubMed Web of Science ®Google Scholar
• Hellkvist L, Hjalmarsson E, Kumlien Georen S, et al. Intralymphatic immunotherapy with 2 concomitant allergens, birch and grass: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2018;142:1338–41 e9.
   PubMed Web of Science ®Google Scholar
• Hylander T, Latif L, Petersson-Westin U, et al. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013;131:412–420.
   PubMed Web of Science ®Google Scholar
• Hylander T, Larsson O, Petersson-Westin U, et al. Intralymphatic immunotherapy of pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled trial. Respir Res. 2016;17:10.
   PubMed Web of Science ®Google Scholar
• Witten M, Malling HJ, Blom L, et al. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013;132:1248–1252.
   PubMed Web of Science ®Google Scholar
• Weinfeld D, Westin U, Hellkvist L, et al. A preseason booster prolongs the increase of allergen specific IgG4 levels, after basic allergen intralymphatic immunotherapy, against grass pollen seasonal allergy. Allergy, Asthma Clin Immunol. 2020;16:31.
   PubMed Web of Science ®Google Scholar
• Thompson CP, Silvers S, Shapiro MA. Intralymphatic immunotherapy for mountain cedar pollinosis: a randomized, double-blind, placebo-controlled trial. Annals of Allergy, Asthma & Immunol. 2020;125:311–318.
   PubMed Web of Science ®Google Scholar
• Skaarup SH, Schmid JM, Skjold T, et al. Intralymphatic immunotherapy improves grass pollen allergic rhinoconjunctivitis: a 3-year randomized placebo-controlled trial. J Allergy Clin Immunol. 2021;147:1011–1019.
   PubMed Web of Science ®Google Scholar
• Skaarup SH, Graumann O, Schmid J, et al. The number of successful injections associates with improved clinical effect in intralymphatic immunotherapy. Allergy. 2021;76:1859–1861.
   PubMed Web of Science ®Google Scholar
• Ahlbeck L, Ahlberg E, Nystrom U, et al. Intralymphatic allergen immunotherapy against pollen allergy: a 3-year open follow-up study of 10 patients. Annals of Allergy, Asthma & Immunol. 2018;121:626–627.
   PubMed Web of Science ®Google Scholar
• Ahlbeck L, Ahlberg E, Björkander J, et al. Intralymphatic immunotherapy with one or two allergens renders similar clinical response in patients with allergic rhinitis due to birch and grass pollen. Clin Exp Allergy. 2022;52:747–759.
   PubMed Web of Science ®Google Scholar
• Ahlbeck L, Ahlberg E, Stuivers L, et al. Intralymphatic immunotherapy with birch and grass pollen extracts. A randomized double-blind placebo-controlled clinical trial. Clin Exp Allergy. 2023. DOI:10.1111/cea.14307.
   PubMed Web of Science ®Google Scholar
• Kundig TM, Johansen P, Bachmann MF, et al. Intralymphatic immunotherapy: time interval between injections is essential. J Allergy Clin Immunol. 2014;133:930–931.
   PubMed Web of Science ®Google Scholar
• Hjálmsdóttir Á, Wäckerle-Men Y, Duda A, et al. Dosing intervals in intralymphatic immunotherapy. Clin Exp Allergy. 2016;46:504–507.
   PubMed Web of Science ®Google Scholar
• Aini NR, Mohd Noor N, Md Daud MK, et al. Efficacy and safety of intralymphatic immunotherapy in allergic rhinitis: a systematic review and meta-analysis. Clin Transl Allergy. 2021;11:e12055.
   PubMed Web of Science ®Google Scholar
• Martínez-Gómez JM, Johansen P, Erdmann I, et al. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2009;150:59–65.
   PubMed Web of Science ®Google Scholar
• Smith KA, Tam VL, Wong RM, et al. Enhancing DNA vaccination by sequential injection of lymph nodes with plasmid vectors and peptides. Vaccine. 2009;27:2603–2615.
   PubMed Web of Science ®Google Scholar
• Šl AY, Senti G, Lang CCV, et al. Quality of life in allergic rhinitis patients treated with intralymphatic immunotherapy (ILIT): a 19-year follow-up. J Allergy Clin Immunol: Global. 2023;2:43–50.
   Google Scholar
• Hjalmarsson E, Hellkvist L, Karlsson A, et al. A five-year open follow up of a randomized, double-blind placebo-controlled trial of intralymphatic immunotherapy for birch and grass reveals remaining beneficial effects. J Investig Allergol Clin Immunol. 2022;33:0.
   Google Scholar
• Hellkvist L, Hjalmarsson E, Weinfeld D, et al. High-dose pollen intralymphatic immunotherapy: two RDBPC trials question the benefit of dose increase. Allergy. 2022;77:883–896.
   PubMed Web of Science ®Google Scholar
• Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129:1290–1296.
   PubMed Web of Science ®Google Scholar
• Zaleska A, Eiwegger T, Soyer O, et al. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine. Allergy. 2014;69:1162–1170.
   PubMed Web of Science ®Google Scholar
• Freiberger SN, Zehnder M, Gafvelin G, et al. IgG4 but no IgG1 antibody production after intralymphatic immunotherapy with recombinant MAT-Feld1 in human. Allergy. 2016;71:1366–1370.
   PubMed Web of Science ®Google Scholar
• Chabot A, Senti G, Erdmann I, et al. Intralymphatic Immunotherapy (ILIT) with bee venom allergens: a clinical proof-of-concept study and the very first ILIT in humans. Front Allergy. 2022;3:832010.
   PubMedGoogle Scholar
• Compalati E, Incorvaia C, Cavaliere C, et al. The role of allergoids in allergen immunotherapy: from injective to sublingual route. Eur Ann Allergy Clin Immunol. 2020;52:195–204.
   PubMed Web of Science ®Google Scholar
• Jensen-Jarolim E, Bachmann MF, Bonini S, et al. State-of-the-art in marketed adjuvants and formulations in allergen immunotherapy: a position paper of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy. 2020;75:746–760.
   PubMed Web of Science ®Google Scholar
• Del Río P R, Vidal C, Just J, et al. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a paediatric assessment. Pediatr Allergy Immunol. 2017;28:60–70.
   PubMed Web of Science ®Google Scholar
• Patel P, Salapatek AM. Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine. Expert Rev Vaccines. 2006;5:617–629.
   PubMed Web of Science ®Google Scholar
• Rosewich M, Lee D, Zielen S. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis. Hum Vaccin Immunother. 2013;9:1523–1531.
   PubMed Web of Science ®Google Scholar
• Zhao X, Wu H, Lin L, et al. Effect and safety analysis of allergovit standardized mite allergen immunotherapy in patients with allergic rhinitis. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2013;27:1128–1131.
   PubMedGoogle Scholar
• Grzeskowiak LE, Tao B, Aliakbari K, et al. Oral immunotherapy using boiled peanuts for treating peanut allergy: an open-label, single-arm trial. Clin Exp Allergy. 2023;53:327–336.
   PubMed Web of Science ®Google Scholar
• Johansen P, Senti G, Martínez Gómez JM, et al. Heat denaturation, a simple method to improve the immunotherapeutic potential of allergens. Eur J Immunol. 2005;35:3591–3598.
   PubMed Web of Science ®Google Scholar
• Jensen-Jarolim E, Roth-Walter F, Jordakieva G, et al. Allergens and adjuvants in allergen immunotherapy for immune activation, tolerance, and resilience. J Allergy Clin Immunol Pract. 2021;9:1780–1789.
   PubMed Web of Science ®Google Scholar
• Kopp MV, Bovermann X, Klimek L. Accelerated dose escalation with three injections of an aluminum hydroxide-adsorbed allergoid preparation of six grasses is safe for patients with moderate to severe allergic rhinitis. Int Arch Allergy Immunol. 2020;181:94–102.
   PubMed Web of Science ®Google Scholar
• Chaker AM, Al-Kadah B, Luther U, et al. An accelerated dose escalation with a grass pollen allergoid is safe and well-tolerated: a randomized open label phase II trial. Clin Transl Allergy. 2015;6:4.
   PubMed Web of Science ®Google Scholar
• Zielen S, Plückhahn K, Akboga Y, et al. Fast up-dosing with a birch allergoid is safe and well tolerated in allergic rhinitis patients with or without asthma. Immunotherapy. 2019;11:177–187.
   PubMed Web of Science ®Google Scholar
• Pfaar O, van Twuijver E, Hecker H, et al. Accelerated up-dosing of subcutaneous immunotherapy with a registered allergoid grass pollen preparation. Int Arch Allergy Immunol. 2013;160:420–424.
   PubMed Web of Science ®Google Scholar
• Mahler V, Zielen S, Rosewich M. Year-round treatment initiation for a 6-grasses pollen allergoid in specific immunotherapy of allergic rhinoconjunctivitis and asthma. Immunotherapy. 2019;11:1569–1582.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Hohlfeld JM, Al-Kadah B, et al. Dose-response relationship of a new Timothy grass pollen allergoid in comparison with a 6-grass pollen allergoid. Clin Exp Allergy. 2017;47:1445–1455.
   PubMed Web of Science ®Google Scholar
• Becker S, Zieglmayer P, Canto G, et al. A meta-analysis on allergen-specific immunotherapy using MCT(®) (MicroCrystalline Tyrosine)-adsorbed allergoids in pollen allergic patients suffering from allergic rhinoconjunctivitis. Clin Transl Allergy. 2021;11:e12037.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Nell MJ, Boot JD, et al. A randomized, 5-arm dose finding study with a mite allergoid SCIT in allergic rhinoconjunctivitis patients. Allergy. 2016;71:967–976.
   PubMed Web of Science ®Google Scholar
• Jutel M, Rudert M, Kreimendahl F, et al. Efficacy and tolerability of a house dust mite allergoid in allergic bronchial asthma: a randomized dose-ranging trial. Immunotherapy. 2018;10:1149–1161.
   PubMed Web of Science ®Google Scholar
• Durham SR. Sustained effects of grass pollen AIT. Allergy. 2011;66(95):50–52.
   PubMedGoogle Scholar
• Durham SR, Emminger W, Kapp A, et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol. 2010;125:131–138.
   PubMed Web of Science ®Google Scholar
• Sidenius K, Arvidsson P, Indbryn R, et al. A real-life one-year non-interventional study assessing safety, tolerability, and treatment outcome of the SQ HDM SLIT-Tablet (Acarizax(®)) in house dust mite allergic rhinitis with or without asthma. Pulm Ther. 2021;7:221–236.
   PubMedGoogle Scholar
• Dorofeeva Y, Shilovskiy I, Tulaeva I, et al. Past, present, and future of allergen immunotherapy vaccines. Allergy. 2021;76:131–149.
   PubMedGoogle Scholar
• Linhart B, Valenta R. Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine. 2012;30:4328–4335.
   PubMed Web of Science ®Google Scholar
• Wraith DC, Krishna MT. Peptide allergen-specific immunotherapy for allergic airway diseases-state of the art. Clin Exp Allergy. 2021;51:751–769.
   PubMed Web of Science ®Google Scholar
• Anderton SM, Viner NJ, Matharu P, et al. Influence of a dominant cryptic epitope on autoimmune T cell tolerance. Nat Immunol. 2002;3:175–181.
   PubMed Web of Science ®Google Scholar
• Burton BR, Britton GJ, Fang H, et al. Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun. 2014;5:4741.
   PubMed Web of Science ®Google Scholar
• Kettner A, DellaCorte G, de Blay F, et al. Benefit of Bet v 1 contiguous overlapping peptide immunotherapy persists during first follow-up season. J Allergy Clin Immunol. 2018;142:678–80.e7.
   PubMed Web of Science ®Google Scholar
• Spertini F, DellaCorte G, Kettner A, et al. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: results of a phase IIb study. J Allergy Clin Immunol. 2016;138:162–168.
   PubMed Web of Science ®Google Scholar
• Ellis AK, Frankish CW, O’Hehir RE, et al. Treatment with grass allergen peptides improves symptoms of grass pollen-induced allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2017;140:486–496.
   PubMed Web of Science ®Google Scholar
• Shamji MH, Ceuppens J, Bachert C, et al. Lolium perenne peptides for treatment of grass pollen allergy: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol. 2018;141:448–451.
   PubMed Web of Science ®Google Scholar
• Mösges R, Bachert C, Panzner P, et al. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: a randomized, multicenter, double-blind, placebo-controlled trial. Allergy. 2018;73:1842–1850.
   PubMed Web of Science ®Google Scholar
• Worm M, Lee HH, Kleine-Tebbe J, et al. Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy. J Allergy Clin Immunol. 2011;127:89–97.
   PubMed Web of Science ®Google Scholar
• Oldfield WL, Kay AB, Larché M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol. 2001;167:1734–1739.
   PubMed Web of Science ®Google Scholar
• Ellis AK, Frankish CW, Armstrong K, et al. Persistence of the clinical effect of grass allergen peptide immunotherapy after the second and third grass pollen seasons. J Allergy Clin Immunol. 2020;145:610–8.e9.
   PubMed Web of Science ®Google Scholar
• Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131:103–109.
   PubMed Web of Science ®Google Scholar
• Oldfield WL, Larché M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet. 2002;360:47–53.
   PubMed Web of Science ®Google Scholar
• Maguire P, Nicodemus C, Robinson D, et al. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol. 1999;93:222–231.
   PubMed Web of Science ®Google Scholar
• Linhart B, Narayanan M, Focke-Tejkl M, et al. Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. Clin Exp Allergy. 2014;44:278–287.
   PubMed Web of Science ®Google Scholar
• Incorvaia C, Al-Ahmad M, Ansotegui IJ, et al. Personalized medicine for allergy treatment: allergen immunotherapy still a unique and unmatched model. Allergy. 2021;76:1041–1052.
   PubMed Web of Science ®Google Scholar
• Jacquet A. Nucleic acid vaccines and CpG oligodeoxynucleotides for allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2021;21:569–575.
   PubMed Web of Science ®Google Scholar
• Su Y, Romeu-Bonilla E, Anagnostou A, et al. Safety and long-term immunological effects of CryJ2-LAMP plasmid vaccine in Japanese red cedar atopic subjects: a phase I study. Hum Vaccin Immunother. 2017;13:2804–2813.
   PubMed Web of Science ®Google Scholar
• Akinfenwa O, Rodríguez-Domínguez A, Vrtala S, et al. Novel vaccines for allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol. 2021;21:86–99.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Bachert C, Bufe A, et al. Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases: s2k guideline of the German society for allergology and clinical immunology (DGAKI), the society for pediatric allergy and environmental medicine (GPA), the Medical Association of German allergologists (AeDA), the Austrian Society for Allergy and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Dermatology (DDG), the German Society of Oto- Rhino-Laryngology, head and neck surgery (DGHNO-KHC), the German Society of Pediatrics and adolescent medicine (DGKJ), the Society for Pediatric Pneumology (GPP), the German Respiratory Society (DGP), the German association of ENT surgeons (BV-HNO), the Professional Federation of Paediatricians and Youth Doctors (BVKJ), the Federal association of pulmonologists (BDP) and the German dermatologists association (BVDD). Allergo J Int. 2014;23:282–319.
   PubMedGoogle Scholar
• Holt PG, Sly PD, Sampson HA, et al. Prophylactic use of sublingual allergen immunotherapy in high-risk children: a pilot study. J Allergy Clin Immunol. 2013;132:991–3.e1.
   PubMed Web of Science ®Google Scholar
• Ponce M, Schroeder F, Bannert C, et al. Preventive sublingual immunotherapy with house dust mite extract modulates epitope diversity in pre-school children. Allergy. 2019;74:780–787.
   PubMed Web of Science ®Google Scholar
• Gradman J, Halken S. Preventive effect of allergen immunotherapy on asthma and new sensitizations. J Allergy Clin Immunol Pract. 2021;9:1813–1817.
   PubMed Web of Science ®Google Scholar
• Weiss R, Scheiblhofer S, Roesler E, et al. Prophylactic mRNA vaccination against allergy. Curr Opin Allergy Clin Immunol. 2010;10:567–574.
   PubMed Web of Science ®Google Scholar
• Crespo JF, Cabanillas B. Recent advances in cellular and molecular mechanisms of IgE-mediated food allergy. Food Chem. 2023;411:135500.
   PubMed Web of Science ®Google Scholar
• Du Toit G, Roberts G, Sayre PH, et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. N Engl J Med. 2015;372:803–813.
   PubMed Web of Science ®Google Scholar
• Flicker S, Marth K, Kofler H, et al. Placental transfer of allergen-specific IgG but not IgE from a specific immunotherapy–treated mother. J Allergy Clin Immunol. 2009;124:1358–60.e1.
   PubMed Web of Science ®Google Scholar
• Wilcock LK, Francis JN, Durham SR. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin Exp Allergy. 2004;34:1373–1378.
   PubMed Web of Science ®Google Scholar
• Durham SR, Ying S, Varney VA, et al. Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol. 1996;97:1356–1365.
   PubMed Web of Science ®Google Scholar
• Gunawardana NC, Durham SR. New approaches to allergen immunotherapy. Annals of Allergy, Asthma & Immunol. 2018;121:293–305.
   PubMed Web of Science ®Google Scholar
• Klimek L, Schmidt-Weber CB, Kramer MF, et al. Clinical use of adjuvants in allergen-immunotherapy. Expert Rev Clin Immunol. 2017;13:599–610.
   PubMed Web of Science ®Google Scholar
• Lu YC, Yeh WC, Ohashi PS. LPS/TLR4 signal transduction pathway. Cytokine. 2008;42:145–151.
   PubMed Web of Science ®Google Scholar
• Sun L, Liu W, Zhang LJ. The role of toll-like receptors in skin host defense, psoriasis, and atopic dermatitis. J Immunol Res. 2019;2019:1824624.
   PubMed Web of Science ®Google Scholar
• Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy. 2009;39:562–570.
   PubMed Web of Science ®Google Scholar
• Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy. 2011;41:1305–1312.
   PubMed Web of Science ®Google Scholar
• Pohlit H, Bellinghausen I, Frey H, et al. Recent advances in the use of nanoparticles for allergen-specific immunotherapy. Allergy. 2017;72:1461–1474.
   PubMed Web of Science ®Google Scholar
• Basomba A, Tabar AI, de Rojas DH, et al. Allergen vaccination with a liposome-encapsulated extract of dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients. J Allergy Clin Immunol. 2002;109:943–948.
   PubMed Web of Science ®Google Scholar
• Igartua M, Hernández RM, Gutierro I, et al. Preliminary assessment of the immune response to Olea Europaea pollen extracts encapsulated into PLGA microspheres. Pharm Dev Technol. 2001;6:621–627.
   PubMed Web of Science ®Google Scholar
• Marazuela EG, Prado N, Moro E, et al. Intranasal vaccination with poly(lactide-co-glycolide) microparticles containing a peptide T of Ole e 1 prevents mice against sensitization. Clin Exp Allergy. 2008;38:520–528.
   PubMed Web of Science ®Google Scholar
• Pecquet S, Leo E, Fritsché R, et al. Oral tolerance elicited in mice by beta-lactoglobulin entrapped in biodegradable microspheres. Vaccine. 2000;18:1196–1202.
   PubMed Web of Science ®Google Scholar
• Joshi VB, Adamcakova-Dodd A, Jing X, et al. Development of a poly (lactic-co-glycolic acid) particle vaccine to protect against house dust mite induced allergy. Aaps J. 2014;16:975–985.
   PubMed Web of Science ®Google Scholar
• Zhang XQ, Dahle CE, Baman NK, et al. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother. 2007;30:469–478.
   PubMed Web of Science ®Google Scholar
• Chew JL, Wolfowicz CB, Mao HQ, et al. Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice. Vaccine. 2003;21:2720–2729.
   PubMed Web of Science ®Google Scholar
• Phase I trial to evaluate VLP peanut in healthy and peanut allergic subjects (PROTECT). Identifier: nCT05476497. [Internet]. Available from: https://clinicaltrials.gov/ct2/show/NCT05476497: [ cited 04 March 2023].
   Google Scholar
• Jensen-Jarolim E. Aluminium in allergies and allergen immunotherapy. World Allergy Organ J. 2015;8:7.
   PubMed Web of Science ®Google Scholar
• Zubeldia JM, Ferrer M, Dávila I, et al. Adjuvants in allergen-specific immunotherapy: modulating and enhancing the immune response. J Investig Allergol Clin Immunol. 2019;29:103–111.
   PubMed Web of Science ®Google Scholar
• Mahler V, Esch RE, Kleine-Tebbe J, et al. Understanding differences in allergen immunotherapy products and practices in North America and Europe. J Allergy Clin Immunol. 2019;143:813–828.
   PubMed Web of Science ®Google Scholar
• Moingeon P. Adjuvants for allergy vaccines. Hum Vaccin Immunother. 2012;8:1492–1498.
   PubMed Web of Science ®Google Scholar
• Lee W, Suresh M. Vaccine adjuvants to engage the cross-presentation pathway. Front Immunol. 2022;13:940047.
   PubMed Web of Science ®Google Scholar
• Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9:847–856.
   PubMed Web of Science ®Google Scholar
• Ho NI, Huis I‘, Veld LGM, et al. Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines? Front Immunol. 2018;9:2874.
   PubMed Web of Science ®Google Scholar
• Leuthard DS, Duda A, Freiberger SN, et al. Microcrystalline tyrosine and aluminum as adjuvants in allergen-specific immunotherapy protect from ige-mediated reactivity in mouse models and act independently of inflammasome and TLR signaling. J Immunol. 2018;200:3151–3159.
   PubMed Web of Science ®Google Scholar
• Fonseca DE, Kline JN. Use of CpG oligonucleotides in treatment of asthma and allergic disease. Adv Drug Deliv Rev. 2009;61:256–262.
   PubMed Web of Science ®Google Scholar
• Kline JN, Waldschmidt TJ, Businga TR, et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol. 1998;160:2555–2559.
   PubMed Web of Science ®Google Scholar
• Rodriguez MJ, Mascaraque A, Ramos-Soriano J, et al. Pru p 3-epitope-based sublingual immunotherapy in a murine model for the treatment of peach allergy. Mol Nutr Food Res. 2017;(10):61. DOI:10.1002/mnfr.201700110
   Web of Science ®Google Scholar
• Montamat G, Leonard C, Poli A, et al. CpG adjuvant in allergen-specific immunotherapy: finding the sweet spot for the induction of immune tolerance. Front Immunol. 2021;12:590054.
   PubMed Web of Science ®Google Scholar
• Garg A, Dewangan HK. Nanoparticles as adjuvants in vaccine delivery. Crit Rev Ther Drug Carrier Syst. 2020;37:183–204.
   PubMed Web of Science ®Google Scholar
• De Souza Rebouças J, Esparza I, Ferrer M, et al. Nanoparticulate adjuvants and delivery systems for allergen immunotherapy. J Biomed Biotechnol. 2012;2012:474605.
   PubMedGoogle Scholar
• Martínez Gómez JM, Fischer S, Csaba N, et al. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles. Pharm Res. 2007;24:1927–1935.
   PubMed Web of Science ®Google Scholar
• Tasaniyananda N, Chaisri U, Tungtrongchitr A, et al. Mouse model of cat allergic rhinitis and intranasal liposome-adjuvanted refined Fel d 1 vaccine. PLoS ONE. 2016;11:e0150463.
   PubMed Web of Science ®Google Scholar
• Arora N, Gangal SV. Immunomodulation by liposome entrapped allergen. Mol Cell Biochem. 1990;97:173–179.
   PubMed Web of Science ®Google Scholar
• Arora N, Gangal SV. Efficacy of liposome entrapped allergen in down regulation of IgE response in mice. Clin Exp Allergy. 1992;22:35–42.
   PubMed Web of Science ®Google Scholar
• Nigam S, Ghosh PC, Sarma PU. Altered immune response to liposomal allergens of aspergillus fumigatus in mice. Int J Pharm. 2002;236:97–109.
   PubMed Web of Science ®Google Scholar
• Hufnagl K, Afify SM, Braun N, et al. Retinoic acid-loading of the major birch pollen allergen Bet v 1 may improve specific allergen immunotherapy: in silico, in vitro and in vivo data in BALB/c mice. Allergy. 2020;75:2073–2077.
   PubMed Web of Science ®Google Scholar
• Roth-Walter F, Afify SM, Pacios LF, et al. Cow’s milk protein β-lactoglobulin confers resilience against allergy by targeting complexed iron into immune cells. J Allergy Clin Immunol. 2021;147:321–334.
   PubMed Web of Science ®Google Scholar
• Baris S, Kiykim A, Ozen A, et al. Vitamin D as an adjunct to subcutaneous allergen immunotherapy in asthmatic children sensitized to house dust mite. Allergy. 2014;69:246–253.
   PubMed Web of Science ®Google Scholar
• Jerzynska J, Stelmach W, Rychlik B, et al. The clinical effect of vitamin D supplementation combined with grass-specific sublingual immunotherapy in children with allergic rhinitis. Allergy Asthma Proc. 2016;37:105–114.
   PubMed Web of Science ®Google Scholar